Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra (NYSE:PEN) and several leading medical organizations announced findings from a comprehensive survey on venous thromboembolism (VTE) care management through their 'Get Out the Clot' campaign. The survey of nearly 270 healthcare professionals revealed significant inconsistencies in blood clot treatment protocols.
Key findings show that only 56% of interventional physicians believe their protocols provide clear direction for pulmonary embolism (PE) risk management, while just 39% feel protocols are clear for deep vein thrombosis (DVT) treatment. Notably, 73% of interventional physicians want expanded use of thrombectomy and computer-assisted vacuum thrombectomy (CAVT) at their hospitals for PE patients, citing benefits like reduced ICU stays (57%) and improved hemodynamics (55%).
The survey also highlighted that more than half of institutions lack formal response teams, and only 35% of physicians report treatment decisions are made by specialty consensus, indicating significant room for improvement in collaborative care approaches.
Penumbra (NYSE: PEN), a leading thrombectomy company, has appointed Shruthi Narayan as its new President, effective September 1, 2025. Narayan, who brings 20 years of medical device industry experience, will report to Adam Elsesser, who continues as chairman and CEO.
Previously serving as president of Penumbra's interventional business, Narayan joined the company in 2013 and has led significant growth in both neuro and vascular franchises. Her experience includes roles at Medtronic and extensive work in engineering, regulatory affairs, and cardiovascular sales.
Penumbra (NYSE: PEN) has announced its upcoming participation in two major healthcare investor conferences. The company will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 8:45 AM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET.
Investors can access the presentation webcasts through Penumbra's website in the "Events and Presentations" section under the "Investors" tab. The recordings will remain available for a minimum of two weeks after each event.
Penumbra (NYSE: PEN) announced its management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 12:30 PM ET/9:30 AM PT.
Investors can access the presentation through a webcast on the company's website under the "Events and Presentations" section of the "Investors" tab at www.penumbrainc.com. The webcast recording will remain available for a minimum of two weeks after the event.
Penumbra (NYSE:PEN), a leading thrombectomy company, reported strong Q2 2025 financial results with revenue of $339.5 million, up 13.4% year-over-year. The company demonstrated robust performance in key segments, with U.S. Thrombectomy revenue reaching $188.5 million, a 22.6% increase, and U.S. VTE revenue growing 42% compared to Q2 2024.
The company achieved net income of $45.3 million with a 13.3% margin and adjusted EBITDA of $61.4 million with an 18.1% margin. Gross profit improved to $224.0 million with a 66.0% margin. Based on strong performance, Penumbra increased its 2025 revenue guidance to $1.355-1.370 billion, representing 13-15% growth over 2024.
Penumbra (NYSE: PEN) has scheduled its second quarter 2025 earnings conference call for July 29, 2025, at 4:30 PM Eastern Time. The company will release its Q2 2025 financial results after market close on the same day.
Investors can access the conference call by dialing (888) 596-4144 with conference ID 6572573, or via webcast through the "Events and Presentations" section on Penumbra's website. The webcast recording will remain available for at least two weeks after the call.
Penumbra Inc (NYSE: PEN) has announced its management team's participation in three upcoming investor conferences in June 2025:
- William Blair 45th Annual Growth Stock Conference on June 3 at 3:00pm ET
- Jefferies Global Healthcare Conference on June 4 at 9:55am ET
- Truist Securities MedTech Conference on June 17 at 10:00am ET
Webcasts of the presentations will be accessible through the "Events and Presentations" section under the "Investors" tab on Penumbra's website and will remain available for at least two weeks after each event.
Penumbra (NYSE: PEN) has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The company's management team will deliver a presentation on Tuesday, May 13, 2025, at 6:00pm ET/3:00pm PT.
Interested parties can access a live webcast of the presentation through the "Events and Presentations" section under the "Investors" tab on Penumbra's official website. The recorded presentation will remain available for viewing on the company's website for a minimum of two weeks following the event.